Sparsentan: the first and only non-immunosuppressive therapy to reduce proteinuria in IgA nephropathy.

IgANephropathy, one of the most common glomerular diseases, is characterized by persistent proteinuria. If proteinuria persists, the patient is at increased risk of developing kidney failure. Therefore, there is an urgent need to find a safe and effective treatment to reduce proteinuria levels in these patients. Sparsentane is a nonimmune dual angiotensin and endothelin receptor antagonist. It has shown promising results in reducing proteinuria in experimental models of glomerular disease and in affected patients.

The safety, tolerability and therapeutic efficacy of sparsentan have been demonstrated in long-term studies in patients with primary glomerular disease over 5 years. The therapeutic effect of sparsentane is more significant in IgA nephropathy compared with FSGS. Therefore, there is sufficient evidence to support sparsentine as a beneficial treatment option. It is expected that sparsentane will become the first-line treatment drug to reduce proteinuria before the use of immunosuppressants to treat IgA nephropathy, replacing the currently commonly used ACEI or ARB. In addition, sparsentane can also be used in combination with other renoprotective drugs such as SGLT inhibitors to further enhance the therapeutic effect.

To ensure that nephrologists can use this new drug safely and effectively in a variety of clinical settings, practice guidelines are needed. These guidelines should include recommendations on the indications, dosage, and duration of sparsentane, with an emphasis on monitoring patients for safety and efficacy. Guidelines like this can promote better care of patients with IgA nephropathy in all clinical settings and ensure they receive optimal outcomes.